GLP-1 injection technique: does it actually affect how well the drug works?

What did @endocrino.cruces actually say?

Honestly, this is a tough one to fact-check, because the transcript is largely incoherent. The video caption promises a guide to GLP-1 injection technique, claiming that "the form of use directly influences effectiveness" and that details like preparation, application zone, and technique "can make a big difference." That framing is the actual claim here. The spoken transcript, however, is garbled, referencing nonsensical terms and locations rather than any clear clinical instruction. We are fact-checking the premise the caption sets up, since that is what 370,000 viewers were sold on.

The core assertion is that improper GLP-1 injection technique reduces drug effectiveness and changes how the body responds. That is a testable, real claim, and it deserves a real answer, even if this creator never actually delivered one.

Does the science back this up?

Yes, partially, but with important nuance. Injection technique does affect subcutaneous drug absorption, though the effect sizes vary by drug and individual. The claim is not wrong in principle, but it is often overstated in wellness content.

A 2022 review by Heise et al. in Diabetes Technology and Therapeutics confirmed that injection site rotation, needle length, and subcutaneous versus intramuscular delivery all affect insulin and GLP-1 analog absorption profiles. Specifically, injecting into scar tissue or lipohypertrophic areas, which develop from repeated injections in the same spot, can delay or reduce drug absorption meaningfully. A 2019 paper by Gentile et al. in Diabetes Research and Clinical Practice found that lipohypertrophy was present in over 50 percent of patients using injectable diabetes medications and was associated with higher HbA1c and more hypoglycemic episodes. So yes, where and how you inject matters. But the difference between "good" and "bad" technique is not a binary switch between effectiveness and failure. Semaglutide and tirzepatide have long half-lives (approximately 7 days and 5 days respectively), which buffers some absorption variability compared to short-acting insulins.

What did they get wrong (or right)?

The caption gets the premise right: technique matters. Credit where it is due. But the video appears to deliver nothing clinically actionable, based on the transcript provided. Viewers watching for actual guidance on GLP-1 injection sites, needle depth, rotation schedules, or storage requirements would have received none of that from this content.

What concerns a fact-checker here is the gap between promise and delivery. The caption uses language designed to generate anxiety, "you might be doing it wrong," without then providing the corrective information. That pattern can push viewers toward unverified sources or, worse, toward adjusting their own doses or technique based on comment-section advice. The specific zones recommended for GLP-1 injections (abdomen, upper thigh, back of upper arm) are standardized in manufacturer labeling for semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Rotating within those zones is the actual guidance. None of that appears to have been communicated here.

What should you actually know?

If you are using a GLP-1 receptor agonist, here is what the evidence actually supports about injection technique.

• Rotate injection sites within approved zones to reduce lipohypertrophy. The abdomen (at least 2 inches from the navel), upper thigh, and upper arm are all approved sites for semaglutide and tirzepatide per their prescribing information.
• Avoid injecting into areas with visible lumps, bruising, or hardened tissue. Heise et al. (2022) and clinical guidelines from the American Diabetes Association both flag this as a meaningful absorption risk.
• Needle length matters less for GLP-1 analogs than for insulin, because these drugs have a wider therapeutic window, but a 4mm to 6mm pen needle is generally appropriate for most adults using subcutaneous delivery.
• Storage temperature affects drug integrity before injection. Semaglutide pens should be stored between 36 and 46 degrees Fahrenheit (2 to 8 degrees Celsius) before first use, and can be kept at room temperature below 86 degrees Fahrenheit for up to 56 days after opening, per Novo Nordisk prescribing information.
• Your prescriber or a certified diabetes care educator is the appropriate person to walk you through technique, not a TikTok video, especially one that does not actually demonstrate anything.